Elsevier

Ophthalmology

Volume 102, Issue 4, April 1995, Pages 647-661
Ophthalmology

Progression of Retinopathy with Intensive versus Conventional Treatment in the Diabetes Control and Complications Trial

https://doi.org/10.1016/S0161-6420(95)30973-6Get rights and content

Purpose: To answer the following questions regarding the effect of intensive diabetes management on retinopathy in insulin-dependent diabetes mellitus (IDDM): (1) Does intensive therapy completely prevent the development of retinopathy? (2) Are some states of retinopathy too advanced to benefit from intensive therapy? (3) Are the retinopathy endpoints in the Diabetes Control and Complications Trial (DCCT) clinically important? and (4) What other factors influence the effectiveness of therapy?

Methods: A total of 1441 patients, ranging in age from 13 and 39 years and with IDDM of 1 to 5 years' duration and no retinopathy at baseline (primary prevention cohort) or with 1 to 15 years' duration and minimal to moderate nonproliferative retinopathy (secondary intervention cohort), were assigned randomly to either intensive or conventional diabetes therapy. Intensive therapy, aimed at achieving glycemic levels as close to the normal range as possible, included three or more daily insulin injections or a continuous subcutaneous insulin infusion, guided by four or more glucose tests daily. Conventional therapy included one or two daily injections. Seven-field stereoscopic fundus photography was performed every 6 months, for a mean follow-up of 6.5 years (range, 4–9 years).

Results: Intensive therapy reduced the risk of any retinopathy (≥ 1 microaneurysm) developing in the primary prevention cohort (70% of intensive versus 90% of conventional treatment group; P = 0.002) by 27%. It reduced the risk of retinopathy developing or progressing to clinically significant degrees by 34% to 76%.Intensive therapy was most effective when initiated early in the course of IDDM. It had a substantial beneficial effect over the entire spectrum of retinopathy studied in the DCCT and, with rare exceptions, in all patient subgroups.

Conclusion: Although intensive therapy does not prevent retinopathy completely, it has a beneficial effect that begins after 3 years of therapy on all levels of retinopathy studied in the DCCT. The reduction in risk observed in the study is translatable directly into reduced need for laser treatment and saved sight. Intensive therapy should form the backbone of any healthcare strategy aimed at reducing the risk of visual loss from diabetic retinopathy.

References (17)

  • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus

    N Engl J Med

    (1993)
  • Design and methodologic considerations for the feasibility phase

    Diabetes

    (1986)
  • The Diabetes Control and Complications Trial DCCT: Update

    Diabetes Care

    (1990)
  • The DCCT Research Group. Implementation of Treatment Protocols in the Diabetes Control and Complications Trial:...
  • Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10

    Ophthalmology

    (1991)
  • Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12

    Ophthalmology

    (1991)
  • Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1

    Arch Ophthalmol

    (1985)
  • Early Treatment Diabetic Retinopathy Study (ETDRS). Manual of Operations. Available from the National Technical...
There are more references available in the full text version of this article.

Cited by (457)

  • Nanotechnology in tissue engineering for diabetes management

    2023, Nanostructured Materials for Tissue Engineering
  • Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics

    2023, Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine
  • Treatment Options for Diabetic Macular Edema

    2024, International Ophthalmology Clinics
View all citing articles on Scopus

Sponsored by the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institutes of Health, Bethesda, Maryland, through cooperative agreements and a research contract, and by the National Heart, Lung and Blood Institute, the National Eye Institute, and the National Center for Research Resources, Bethesda, Maryland.

*

A complete listing of the Diabetes Control and Complications Trial Research Group can be found in Arch Ophthalmol 1995;113:36-51.

View full text